Stay updated with breaking news from Agenus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Agenus , a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab in combination with... | May 3, 2023
Shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price […]
Agenus (NASDAQ:AGEN – Get Rating) and Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership. Analyst Recommendations This is a summary of recent ratings for […]
Clinical-stage immuno-oncology company Agenus Inc. (GEN) Monday said the US Food and Drug Administration has granted Fast Track Designation for the investigation of the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034).
Agenus Inc. , a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, has been granted Fast Track Designation from the US Food and Drug... | April 17, 2023